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Deleterious Variants of FIG4,
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in Patients with ALS
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Mutations of the lipid phosphatase FIG4 that regulates PI(3,5)P2 are responsible for the recessive peripheral-nerve disorder CMT4J. We
now describe nonsynonymous variants of FIG4 in 2% (9/473) of patients with amyotrophic lateral sclerosis (ALS) and primary lateral
sclerosis (PLS). Heterozygosity for a deleterious allele of FIG4 appears to be a risk factor for ALS and PLS, extending the list of known
ALS genes and increasing the clinical spectrum of FIG4-related diseases.FIG4, also known as SAC3, is a phosphoinositide 5-phos-
phatase that regulates the cellular abundance of
PI(3,5)P2, a signaling lipid located on the cytosolic surface
of membranes of the late endosomal compartment.1
PI(3,5)P2 mediates retrograde trafﬁcking of endosomal
vesicles to the trans-Golgi network.2,3 Inactivation of
FIG4 in mice results in massive degeneration of neurons
in sensory and autonomic ganglia, motor cortex, striatum,
and other regions of the central nervous system, with
extensive vacuolization of neurons and other cells.4
Sciatic-nerve-conduction velocity is reduced and motor
neurons in the ventral spinal cord are vacuolated in homo-
zygous null mice.
Mutations of the human FIG4 gene on chromosome
6q21 are responsible for the recessively inherited disorder
CMT4J (MIM 611228), a severe form of Charcot-Marie-
Tooth disease (CMT) with early onset and involvement
of both sensory and motor neurons.4 CMT4J patients are
compound heterozygotes with a loss-of-function allele in
combination with the partial loss-of-function mutation
I41T. FIG4 mutations were found in four families, and
childhood onset occurred in three families. One family ex-
hibited adult onset and primarily motor symptoms that
resembled amyotrophic lateral sclerosis (ALS) (MIM
105400), except for reduced nerve-conduction velocity
and segmental demyelination indicative of Schwann cell
involvement.5 Because mutation of FIG4 affects motor-
neuron function in humans and mice, we tested FIG4 as
a candidate gene for ALS.
ALS is a severe neurological disorder, with onset between
40 and 80 years of age, characterized by selective neurode-
generation of lower and upper motor neurons in the spinal
cord, brainstem, and cortex.6,7 PLS (MIM 611637) is
a relatedmotor-speciﬁc disorder that primarily affects corti-The Acospinal upper motor neurons.6,7 Ninety percent of ALS
cases are sporadic (SALS), and 10% have a familial history
(FALS), usually with dominant inheritance. ALS is geneti-
cally heterogeneous, and known genes explain < 5% of
cases.6,7 PLS is usually sporadic, and genetic defects have
not been identiﬁed. To evaluate the role of FIG4, we
screened DNA from 473 patients, including 364 sporadic
cases and 109 familial cases.
All patients and controls were of European ancestry.
SALS cases included individuals from National Institute
of Neurological Disorders and Stroke panels NDPT025
(long-term ALS survivors), NDPT026 (bulbar onset), and
NDPT029 (upper-limb onset) (see Web Resources), as well
as 92 SALS patients from the Massachusetts General
Hospital who had onset at 53 5 15 years (mean 5 SD),
a disease duration of 4.8 5 4 years, and a male to female
ratio of 2:1. The site of disease onset was 23% bulbar,
43% upper extremities, 28% lower extremities, and 7%
multiple sites, The FALS patients had onset at 55 5 15
years (median 55 years) and disease duration of 3.4 5 3.2
years, with a male to female ratio of 1:1.3. The FALS
patients were previously tested for mutations in SOD1;
their site of disease onset was 27% bulbar, 31% upper
extremities, 37% lower extremities, and 5% multiple sites.
All procedures were carried out in accordance with the
ethical standards of the Institutional Review Boards at
the Massachusetts General Hospital and the University of
Michigan.
To screen for pathogenic mutations in the coding
sequence and splice sites, we ampliﬁed the 23 exons of
FIG4 from 473 patient genomic-DNA samples. Eleven
exons were sequenced directly for all patients (exons 2,
7, 8, 9, 10, 17, 18, 19, 20, 21, and 23). The other 12
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Table 1. Rare Variants of FIG4 in Patients with ALS and PLS
Sample Amino Acid Exon Nucleotide
Controls
(Frequency)
Polyphen
Score
Sift
Score Comments
Predicted
Deleterious
El Escorial
Diagnosis
SALS E12 p.R183X exon 6 c.547C/T 0/558 n.a. n.a Truncation before
active site
Yes ALS definite
SALS 8533 p.Q403X exon 11 c.1207C/T 0/558 n.a. n.a. Truncation before
active site
Yes ALS possible
FALS G07 p.R23fsX30
or p.del(23–55)
exon 2
splice site
c.671G/T 0/558 n.a n.a. Truncation or
deletion of 33 aa
Yes ALS suspected
ND 09489 p.S424_K462
del insR
exon 12
splice site
c.1386þ5G/T 0/395 n.a. n.a Deletion in active site
domain or truncation
Yes ALS definite
FALS G03 p.D53Y exon 2 c.157G/T 0/558 3 2 Impaired in yeast Yes ALS definite
SALS B12 p.D48G exon 2 c.143A/G 0/558 2 1 Functional in yeast No PLS possible
SALS H11 p.R388G exon 11 c.1162A/G 0/558 1 1 Impaired in yeast No PLS
SALS E12 p.I411V exon 11 c.1231A/G 0/558 1 1 Functional in yeast No ALS definite
ND 11318 p.Y647C exon 17 c.1940T/G 0/395 2 1 Not conserved in yeast unclear ALS definite
FALS A04 p.I902T exon 23 c.2705T/C 0/558 2 2 Not conserved in yeast unclear ALS definite
PolyPhen scores are as follows: 1, benign; 2, possibly damaging; 3, probably damaging. SIFT scores are as follows: 1, tolerated; 2, affects protein structure.
The first five of the ten variants and R388G are highly likely to be pathogenic. ‘‘n.a.’’ indicates not applicable (not missense). For clinical descriptions of
these patients, see Table S1 SALS, plate 1p1. FALS, plate 1p2.(conformation-sensitive gel electrophoresis),8 and exons
with abnormal mobility were sequenced. Small deletions
or duplications could have been missed by our screening
methods. All variants were conﬁrmed in at least two inde-
pendent PCR and sequencing reactions. For the detection
of possible second-site mutations, all 23 exons were
sequenced for the individuals in Table 1.
Variants detected in the patients were tested in 395–558
ethnically matched controls. Control samples from the Cor-
iell Institute include 192 samples from the neurological
normal control panels NDPT006 and NDPT009 and 163
neurologically normal individual samples that did not over-
lap with the panels. A set of 111 controls older than 60 years
of age without personal or family history of neurological
disease was previously described.9 Spouses of ALS patients
provided 92 controls. SNPs detected in patients and controls
are presented in Table S2, available online.
We identiﬁed ten unique nonsynonymous variants of
FIG4 in nine patients, including six with SALS and three
with FALS (Table 1). Seven patients carried a diagnosis of
deﬁnite or probable ALS, and two patients carried a diag-
nosis of PLS, with average age of onset of 56 5 14 years
(mean 5 SD) and average duration of 9 5 11 years. Clin-
ical ﬁndings for these patients are presented in Table S1.
There was a striking prominence of corticospinal ﬁndings.
Subtle changes in personality were mentioned in two
cases.
Eachmutation was found in a single patient and was not
present in controls (Table 1) or in the dbSNP, indicating
that they are not common polymorphisms . The variants
include two protein-truncation mutations, two mutations
in consensus splice sites, and six missense mutations
(Table 1). Sequence chromatograms and evolutionary
conservation are presented in Figure S1.
The two protein-truncation mutations, R183X and
Q403X, are located upstream of the SAC phosphatase86 The American Journal of Human Genetics 84, 85–88, January 9, 2active site10,11 and result in loss of FIG4 phosphatase
activity.
The exon 2 splice acceptor mutation alters the invariant
1G nucleotide, which prevents correct splicing. This
mutation created a novel out-of-frame consensus acceptor
site 2bpdownstreamof theoriginal site (Figure S1). Splicing
to the new site is strongly predicted fromanalysis of human
mutations at the 1 position.12 This outcome would result
in the protein truncation R23fsX30. Skipping of exon 2
would result in an in-frame deletion of 33 evolutionarily
conserved amino acids, likely to interfere with protein
function.
The splice-site mutation in the donor site of exon 12
changes the important þ5G residue that is the site of
many human mutations.13 The predicted outcome is skip-
ping of exon 12, resulting in an in-frame deletion of 39
amino acid residues from the SAC phosphatase domain.13
Alternatively, readthrough into intron 12 would generate
the in-frame stop codon K463fsX474. Cell lines from these
patients were not available for analysis of splice products.
The six missense mutations were analyzed with the
protein-prediction programs PolyPhen and SIFT (see Web
Resources). D53Y was most strongly predicted to be delete-
rious (Table 1). Four of the missense mutations change
amino acid residues that are conserved in yeast; we tested
their ability to rescue the enlarged vacuole in a Fig4D
null yeast strain. To be functional in the yeast assay,
the variant protein must bind the other proteins in
the PI(3,5)P2-regulatory complex, become localized to the
vacuolar membrane, and retain phosphatase activity.14
Consistent with the predictions, D53Y is a deleterious
allele, with less activity than wild-type FIG4 (p < 0.001)
and less activity than the CMT4J mutant allele I41T, which
was included for comparison (p< 0.02) (Figure 1A). R388G
also has signiﬁcantly less activity than the wild-type allele
(p < 0.02). The variants D48G and I411V were close to the009
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Figure 1. Rescue of Vacuole Formation in Null Fig4D Yeast
(A) Patient missense mutations were introduced into yeast Fig4p and tested for their ability to correct the enlarged vacuole in a Fig4D
null strain of yeast as previously described.4,8 The pathogenic CMT4J variant I41T was included for comparison. The low level of PI(3,5)P2
in Fig4D cells results in enlarged vacuoles, and introduction of wild-type Fig4p restores both PI(3,5)P2 levels and vacuole morphology.
4,8
Bars represent the mean from three independent experiments, containing 100–300 cells per experiment. p values for each mutant
compared with the wild-type were calculated with the unpaired t test.
(B) Locations of patient mutations.wild-type in function, and their pathogenicity remains
uncertain (Figure 1A). Mutations D48G and D53Y are
located at two ends of a predicted b-sheet domain, consis-
tent with an effect on protein interaction.
Overall, six of the ten variants are clearly deleterious: the
two stop codons, the two consensus splice-site variants, and
the missense mutations D53Y and R388G (Figure 1B). The
SALS patient E12 carried two variants, R183X and I411V.
Because I411V retained full function in the yeast assay, it
is unlikely to contribute todisease. Theother threemissense
variants inTable 1couldbepathogenic aswell.DNAwasnot
available fromfamilymembers for analysis of cosegregation
of the FALS variants. The missense mutations were identi-
ﬁed in single patients, and detection in additional patients
would support their pathogenicity.
In our previous work on CMTJ4 families, we observed
two parents and one sibling who were heterozygous
carriers of null alleles of FIG4 but did not exhibit clinical
symptoms.4 These individuals were younger than our
patients with late-onset ALS and could be presymptomatic
or reﬂect incomplete penetrance. Heterozygous missense
mutations of FIG4 could exert their effects either through
partial loss of function or by a dominant-negative mecha-
nism via competition with the wild-type protein for incor-
poration into the multimeric PI(3,5)P2-regulatory
complex.14 The variable age at onset in CMT4J families,
from early childhood to adulthood, suggests that genetic
background and/or environmental exposures modify the
clinical course. These factors are also thought to inﬂuence
manifestation of ALS caused by mutations in other genes.
The known role of FIG4 in motor-neuron survival and the
impaired function of the patient-speciﬁc variants
described here support the view that these mutations
contribute to the development of ALS.The ACMT4J patients derive all of their FIG4 activity from one
copy of the defective allele I41T; as a result, they have less
FIG4 activity than the ALS patients, who have one wild-
type allele in addition to their defective allele. Most
CMT4J patients have onset in early childhood and a severe
course. The adult-onset CMT4J patients differ from ALS
patients by their Schwann cell involvement, as indicated
by reduced nerve-conduction velocity and sural-nerve
demyelination.5 The ALS patients and adult-onset CMT4J
patients both exhibit asymmetric progression, absence of
sensory symptoms, and the absence of dementia. The ALS
and PLS cases have normal conduction velocities and
striking corticospinal-tract signs. In the SALS cases, the cor-
ticospinal signs were the most salient ﬁndings (Table S1).
Similarly, in FIG4 null mice, neurodegeneration is much
earlier and more extensive in the motor cortex than in
spinal motor neurons.4
Phosphoinositides serve as molecular tags for intracel-
lular vesicles and mediate vesicle trafﬁcking. Other genes
affecting phosphoinositide signaling are responsible for
Charcot-Marie-Tooth type 4B1, 4B2, and 4H, and SPG15,
which targets corticospinal motor neurons.15–19 Phosphoi-
nositide metabolism has not been previously implicated in
ALS. Human motor neurons could be particularly suscep-
tible to mutations that affect membrane trafﬁcking
because of their need to turnover membrane components
from long axonal processes during many decades of life.1
Each of the previously identiﬁed ALS genes account for
only a few percent of cases.6,20 The identiﬁcation of FIG4
mutations in 1%–2% of ALS patients suggests that FIG4
is another contributor to this genetically heterogenous
disease. More extensive screening will be needed for
a precise deﬁnition of the contribution of FIG4 to ALS
and other motor-neuron disorders.merican Journal of Human Genetics 84, 85–88, January 9, 2009 87
Supplemental Data
Supplemental Data include one ﬁgure and two tables and are
available with this paper online at http://www.ajhg.org/.
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